 |
市场调查报告书
商品编码
2008170
人类胚胎干细胞市场：依产品和地区划分Human Embryonic Stem Cells Market, By Product (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing) , By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) |
||||||
预计2026年，人类胚胎干细胞（人类ES细胞）市场规模将达15亿美元，2033年将达21亿美元。预计从2026年到2033年，其复合年增长率将达到9.72%。
| 分析范围 | 分析详情 | ||
|---|---|---|---|
| 基准年 | 2025 | 市场规模（2026 年） | 15亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2026-2033 |
| 预测期（2026-2033 年）复合年增长率 | 9.72% | 预计金额（2033 年） | 21亿美元 |
干细胞是一种能够分化成其他类型细胞的生物细胞，可用于治疗目的。近年来，随着技术的进步和技术创新，干细胞疗法开闢了许多潜在的治疗方法，使得人类胚胎干细胞治疗方法在全球范围内广泛应用。人类胚胎干细胞正逐渐成为细胞治疗领域极具潜力的候选细胞，能够修復受损细胞和组织的功能。此外，人类胚胎干细胞（hESCs）具有巨大的治疗潜力，有望成为心臟病和恶性肿瘤的标准治疗方法。
市场动态
心臟病和恶性肿瘤发病率上升、对干细胞治疗方法的研发日益关注、再生医学需求不断增长以及政府和私营机构的支持力度加大，预计这些因素将推动全球人类胚胎干细胞市场在预测期内增长。
例如，2021 年 4 月，Vertex Pharmaceuticals 获得了美国食品药物管理局(FDA) 授予的 VX-880简审类，并开始对 1 型糖尿病、严重低血糖症和低血糖识别能力受损的患者进行 VX-880 的临床试验。
2020年2月，全球干细胞治疗与研究中心（GIOSTAR）宣布在印度开设新的干细胞、癌症研究与治疗中心。该中心的成立标誌着GIOSTAR全球扩张策略的最新里程碑，其主导印度、墨西哥、美国等众多国家。
本报告的主要特点
- 本报告对全球人类胚胎干细胞市场进行了详细分析，包括市场规模和预测期（2026-2033 年）的复合年增长率，以 2025 年为基准年。
- 此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
- 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本节根据以下参数，对全球人类胚胎干细胞市场的主要企业进行介绍：公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
- 《全球人类胚胎干细胞市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过分析全球人类胚胎干细胞市场中使用的各种策略矩阵来促进决策。
目录
第一章：分析目标与假设
- 分析目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章：市场动态、监管与趋势分析
- 市场动态
- 促进因素
- 抑制因子
- 市场机会
- 影响分析
- 市场趋势
- 主要进展
- 产品核准
- 商业伙伴关係、企业合併
- 监理情势
- PEST分析
- 波特五力分析
- 流行病学
- 固体管道分析
第四章：全球人类胚胎干细胞市场：依产品分类（2026-2033 年）
- 再生医学
- 干细胞生物学概览
- 组织工程
- 毒性测试
第五章：全球人类胚胎干细胞市场：依地区划分（2026-2033年）
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 中东
- GCC
- 以色列
- 其他中东国家
- 非洲
- 北非
- 中非
- 南非
第六章 竞争情势
- 热图分析
- 市占率分析
- 公司简介
- Takara Bio Inc.
- ViaCyte Inc.
- PromoCell GmbH
- Merck KgaA
- PeproTech Inc.
- Astellas Pharma Inc.
- Thermo Fisher Scientific
- Lineage Cell Therapeutics Inc.
- STEMCELL Technologies Inc.
第七章
- 参考
- 分析方法
- 关于 Coherent Market Insights
Human Embryonic Stem Cells Market is estimated to be valued at USD 1.5 Bn in 2026 and is expected to reach USD 2.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.72% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.72% | 2033 Value Projection: | USD 2.1 Bn |
Stem cells are biological cells that can differentiate into other types of cells, and are used for therapeutic purposes. Recent developments or advancements have paved the way for a plethora of potential therapies, due to which, therapies involving human embryonic stem cells are being widely adopted worldwide. Human embryonic stem cells have emerged as attractive candidates for cell-based therapies that are capable of restoring lost cell and tissue function. Furthermore, human embryonic stem cells (hESC) have a high potential for use in treatment and may become a standard of care for cardiac and malignant diseases.
Market Dynamics
Rise in incidence of cardiac and malignant diseases, increase in focus on the development of stem cell-based therapies, growing demand for regenerative medicines, and increasing support from government and private organizations are major factors expected to drive growth of the global human embryonic stem cells market during the forecast period.
For instance, in April 2021, Vertex Pharmaceuticals received the United States Food and Drug Administration (FDA) Fast Track Designation for VX-880, and the company initiated a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness.
In February 2020, Global Institute of Stem Cell Therapy and Research (GIOSTAR) announced the inauguration of a new stem cell / cancer research and therapy center in India. This facility represents the latest milestone in global expansion efforts spearheaded by GIOSTAR in India, Mexico, the United States, and numerous other countries.
Key features of the study
- The report provides in-depth analysis of the global human embryonic stem cells market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global human embryonic stem cells market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global human embryonic stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human embryonic stem cells market.
Market Segmentation
- By Product
- Regenerative Medicine
- Stem Cell Biology Research
- Tissue Engineering
- Toxicology Testing
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Takara Bio Inc.
- ViaCyte Inc.
- PromoCell GmbH
- Merck KgaA
- PeproTech Inc.
- Astellas Pharma Inc.
- Thermo Fisher Scientific
- Lineage Cell Therapeutics Inc.
- STEMCELL Technologies Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Human Embryonic Stell Cells Market, By Product, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Stem Cell Biology Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Tissue Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
5. Global Human Embryonic Stell Cells Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
6. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Takara Bio Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ViaCyte Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PromoCell GmbH
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck KgaA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PeproTech Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lineage Cell Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- STEMCELL Technologies Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
7. Section
- References
- Research Methodology
- About Us
